via ft.com
The company told the Financial Times: “Roche plans to set up a multi-party advisory board comprising experts from academia and private institutions, including the Cochrane Collaboration, to review the totality of Tamiflu data with the objective to agree on a statistical analysis plan outlining the types of analyses that would be useful in a public health discussion on Tamiflu.”
No comments:
Post a Comment